CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 148 target
Drug / intervention
Toripalimab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06323239
NCT06323239Phase 2RecruitingOn Track
CompareCT.gov

Stereotactic Body Radiotherapy (SBRT) and Low-dose Radiotherapy (LDRT) Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Single-arm, Phase II Clinical Trial

Sun Yat-sen University·interventional·Posted Mar 21, 2024·Updated May 11, 2026

In Brief

A Phase 2 clinical trial evaluating SBRT, Low-dose Radiotherapy (LDRT), and 4 other interventions for Nasopharyngeal Carcinoma. Currently recruiting, targeting 148 participants across 1 site.

Detailed Summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
20252026202720282029
First PostedMar 21, 2024
Enrollment StartJul 15, 2024
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 2.3 years agoPrimary completion in 5 months

Interventions

SBRTradiation

SBRT for metastatic lesions

Low-dose Radiotherapy (LDRT)radiation

LDRT for metastatic lesions

Toripalimabdrug

6 cycles for combined therapy. Toripalimab maintenance for 1 year.

Gemcitabinedrug

6 cycles for combined therapy.

Cisplatindrug

6 cycles for combined therapy.

IMRTradiation

IMRT for primary lesion